New data bolster Stelara's case for shift to first-line psoriasis treatment
This article was originally published in Scrip
Additional positive data on one of Janssen's (Johnson & Johnson) key future growth drivers, the biological psoriasis treatment Stelara (ustekinumab), are helping to create the mood music that could ease its passage into first-line therapy.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.